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OBJECTIVE— The aim of this study was to determine the effect of common adiponectin
gene polymorphisms on dietary intervention-mediated changes in adiponectin levels and ho-
meostasis model assessment of insulin resistance (HOMA-IR) indexes.
RESEARCHDESIGNANDMETHODS— A total of 363 subjects with impaired fasting
glucose (IFG) or newly diagnosed type 2 diabetes followed a dietary intervention (replacement
of cooked refined rice with whole grains and an increase in vegetable intake) and regular walking
for 12 weeks without any medication. Adiponectin gene single nucleotide polymorphisms
(SNPs) (45, 276, and 11377) were examined in these subjects.
RESULTS— After this dietary intervention, fasting glucose levels decreased in all three SNP
45TG genotype groups. Subjects with the SNP 45TT genotype showed increased adiponectin
levels and decreased HOMA-IR indexes. Haplotype analysis revealed that homozygous carriers
of the TG haplotype (45TT and 276GG) and heterozygous carriers of the TG haplotype (TG/X)
showed a reduction in the HOMA-IR index after adjustment for baseline levels. Significant
differences were observed in changes in HOMA-IR indexes and adiponectin concentrations
according to the 45-276 TG haplotype in overweight-obese, but not in normal-weight subjects:
the greatest decrease in HOMA-IR indexes and the greatest increase in adiponectin levels were
shown in overweight-obese subjects with the TG/TG haplotype.
CONCLUSIONS— ADIPOQ genetic variants can affect circulating adiponectin levels and
insulin resistance indexes in subjects with IFG or newly diagnosed type 2 diabetes in response to
dietary intervention.
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Adiponectin is a protein producedand secreted by adipocytes that in-fluences the body’s response to in-
sulin. It is encoded by the ADIPOQ gene
on chromosome 3q27 (1) in a region pre-
viously identified through genetic linkage
studies as a diabetes susceptibility locus
(2). Several single nucleotide polymor-
phisms (SNPs) in the ADIPOQ gene have
been shown in Japanese and European
populations to be associated with diabetes
(3–5) or insulin resistance syndrome (6).
However, previous work on ADIPOQ
SNPs have shown that the SNPs associ-
ated with type 2 diabetes or circulating
adiponectin levels differ according to
both the study cited and the ethnic pop-
ulation studied. Specifically, SNPs
276GT (intron 2) and 45TG (exon 2)
have been associated with various levels
of adiponectin as well as BMI, fasting in-
sulin concentration, and homeostasis
model assessment of insulin resistance
(HOMA-IR) in nondiabetic Koreans (7).
Circulating levels of adiponectin are
unlikely to be affected by acute dietary
changes but rather reflect dietary intake
over time (8). However, little is known
about the dietary modulation of plasma
adiponectin levels in humans. Although
humans differ in their responses to diet
and many of these differences can be due
to genetic polymorphisms (9,10), the ma-
jority of previous studies have considered
the ADIPOQ gene only in relation to the
degree of insulin resistance syndrome
without considering responses to dietary
intervention. Recently, a carbohydrate-
rich diet with a high glycemic load was
found to be associated with lower adi-
ponectin levels (8). According to the 2005
Korean National Health and Nutrition
Survey (11), carbohydrate-derived calo-
ries account for 64% of total caloric in-
take, and cooked refined rice is the major
source of carbohydrates in middle-aged
adults. Because of this high carbohydrate
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intake, the replacement of refined rice
with whole grains and legumes has been
suggested as a way to reduce the risk fac-
tors for type 2 diabetes (12). Therefore,
we determined the effects of dietary inter-
vention (replacement of refined rice with
whole grains, a high intake of vegetables,
and regular exercise) on circulating adi-
ponectin levels and insulin resistance in-
dexes in conjunction with common
adiponectin gene polymorphisms in Ko-
reans with impaired fasting glucose (IFG)
or newly diagnosed type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Study subjects were se-
lected from participants in a nutrition
genomic study conducted by the National
Research Laboratory of Clinical Nutrige-
netics/Nutrigenomics (Program R0A-
2005-000-10144-0) at Yonsei University.
Study subjects were recruited from the
Health Service Center or the outpatient
clinics at Yonsei University Severance
Hospital in Seoul, Korea, and National
Health Insurance Corporation Ilsan Hos-
pital in Goyang, Korea.
Subjects with a diagnosis of type 2
diabetes or IFG who consented to the di-
etary intervention program were in-
cluded. Hyperglycemia was defined
according to the American Diabetes Asso-
ciation criteria (9), in which diabetes is
defined as fasting glucose 126 mg/dl,
and IFG is defined as fasting glucose be-
tween 100 and 125 mg/dl. Exclusion cri-
teria included 1) previous history of
diabetes, 2) abnormal liver or renal func-
tion, 3) history of cardiovascular disease
and cancer, 4) unstable weight loss/gain
(2 kg) over the previous 6 months, and 5)
thyroid or pituitary disease. A total of 430
Koreans were recruited, and 67 participants
discontinued the study for personal rea-
sons. Finally, 363 subjects completed the
study program. All subjects gave their writ-
ten informed consent for the study, which
was approved by the Institutional Review
Board of Yonsei University.
Detailed methods for the genotyping
of ADIPOQ SNPs (11377, 45, and 276)
and clinical laboratory tests were de-
scribed previously (7).
Dietary intervention program and
assessment of dietary
intake/physical activity level
A 12-week dietary intervention program
was conducted. The subjects’ usual diets
were assessed using a semiquantitative
food frequency questionnaire and a 24-h
recall method at baseline. All subjects
were given written and verbal instruc-
tions by a registered dietitian on how to
complete a 3-day dietary record every 4
weeks. Individualized and nutritionally
balanced diets were planned for each sub-
ject at the initial visit. The dietary inter-
vention program consisted of the
replacement of refined rice with whole
grains three times a day as a carbohydrate
source and an increase in vegetable intake
to at least 6 units (30–70 g/unit) per day
for sufficient dietary fiber intake. The sub-
jects were told to drink no more than one
alcoholic beverage drink (15 g alcohol)
per day and were assigned physical activ-
ity, comprising a regular 30-min walk af-
ter dinner each day.
The energy values and nutrient con-
tent of dietary intake were calculated us-
ing the Computer Aided Nutritional
Analysis Program (CAN-Pro 2.0, Korean
Nutrition Society). Total energy expendi-
tures were calculated from activity pat-
terns including basal metabolic rate (by
the Harris-Benedict equation), physical
activity for 24 h, and the specific dynamic
action of food.
Statistical analysis
Hardy-Weinberg equilibrium, linkage
disequilibrium (LD), and haplotype fre-
quencies were determined by Haploview
(version3.32;http://www.broad.mit.edu/
mpg/haploview/), and subject-specific
haplotypes were estimated using the Hap-
Analyzer program (http://hap.ngri.go.kr)
with the EM algorithm. We also used
SPSS (version 12.0 for Windows; SPSS,
Chicago, IL). A paired t test was used to
evaluate the effect of dietary intervention.
ANOVA with the Bonfer-roni method or a
general linear model was used to test the
genotype or haplotype effects. Pearson
and partial correlation coefficients were
used to examine the relationship between
adiponectin levels and other metabolic
variables. Finally, a multiple linear
regression analysis was performed to find
independent effects on changes in adi-
ponectin levels after dietary intervention.
Each variable was examined for normal
distribution, and the skewed variables
were tested after logarithmic trans-
formation. For descriptive purposes,
mean values are presented on untrans-
formed and unadjusted variables. P  0.
05 was considered statistically significant.
RESULTS
Distribution of ADIPOQ SNPs in the
study population (n  363)
All SNPs were in Hardy-Weinberg equi-
librium (P  0.05). SNP 11377 con-
tained 56.5% C/C, 36.6% C/G, and 6.9%
G/G (C frequency 0.748). SNP 45 con-
tained 49.3% T/T, 41.9% T/G, and 8.8%
G/G (T frequency  0.703). SNP 276
contained 52.3% G/G, 39.4% G/T, and
8.3% T/T (G frequency 0.720). LD was
calculated between the three SNPs: low
LD between SNP 45TG and SNP
11377CG (D  0.692; P  0.001)
and between SNP 276GT and SNP
11377CG (D  0.003, P  0.092)
and complete, strong LD between SNP
45TG and SNP 276GT (D  1;
P 0.001). Accordingly, haplotype anal-
ysis was performed for SNP 45TG com-
bined with SNP 276GT. Estimated 45–
276 haplotype frequencies were 17.8%
for TG/TG, 22.8% for TG/TT, 25.7% for
TG/GG, 8.1% for TT/TT, 16.3% for TT/
GG, and 9.2% for GG/GG. In subsequent
statistical analyses, subjects were divided
into three haplotype groups: homozygous
for the TG haplotype (TG/TG; n  65)
and heterozygous for the TG haplotype
(TG/X; n  177) and non-TG haplotype
(X/X; n  121).
Clinical characteristics and nutrient
intake both before and after dietary
intervention. The 12-week dietary in-
tervention increased HDL cholesterol but
significantly decreased blood pressure
and serum concentrations of glucose, tri-
glycerides, total cholesterol, and LDL
cholesterol (Table 1). Adiponectin levels
were slightly but not significantly higher
after dietary treatment. There were signif-
icant increases from baseline in both fiber
intake and the polyunsaturated fatty ac-
ids–to–saturated fatty acids ratio and a
slight increase in total energy expenditure
but a decrease in total energy intake. The
mean body weights of the study partici-
pants were slightly but significantly re-
duced after dietary intervention (Table 1).
Baseline characteristics, adiponectin
levels, and HOMA-IR indexes
according to ADIPOQ SNP genotypes
There were no significant differences in
terms of sex distribution, age, and BMI
associated with SNP 45 (Table 2), SNP
276 (Table 2), and SNP11377 (data not
shown) genotypes. At baseline, we did
not observe any significant genotype-
related associations between the three
SNPs and plasma adiponectin levels.
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However, for SNP 276, baseline serum
glucose levels were significantly higher in
GG subjects than in TG and TT subjects
(Table 2). For the 45TG/276GT hap-
lotypes, TG/TG subjects showed higher
insulin levels and HOMA-IR indexes than
did non-TG subjects (X/X) (Table 2).
Effect of a 12-week dietary
intervention on HOMA-IR indexes
and adiponectin levels in relation to
ADIPOQ SNP genotype
Regardless of the SNP 45TG genotype,
the dietary intervention significantly de-
creased serum glucose levels without any
significant increase in insulin levels (Ta-
ble 2). After the dietary intervention,
HOMA-IR indexes were reduced in sub-
jects carrying the SNP 45T allele. SNP
45TT subjects also had a mean adiponec-
tin level increase of 0.48  0.17 g/ml
(10.9%). There was a significant geno-
type-related difference in insulin levels
(P  0.005), HOMA-IR indexes (P 
0.049), and adiponectin levels (P 
0.037) for SNP 45.
After the 12-week trial, serum glucose
levels were reduced in subjects carrying
the SNP 276G allele, and HOMA-IR in-
dexes were reduced in SNP 276GG sub-
jects (Table 2). There was initially a
significant decrease in HOMA-IR indexes
among the genotypes (P  0.025), but
this difference disappeared after adjust-
ment for the baseline levels (P  0.074).
In the 45–276 haplotype analysis (Ta-
ble 2) after the 12-week trial, serum glu-
cose levels were significantly decreased in
a l l hap lo type groups . However ,
HOMA-IR indexes were reduced only in
subjects carrying the TG haplotypes
(TG/TG  TG/X) but not in the non-TG
subjects (X/X). There were significant dif-
ferences in insulin levels (P 0.001) and
HOMA-IR indexes (P 0.001) regarding
the 45–276 haplotype, even after adjust-
ment for baseline insulin (P 0.005) and
HOMA-IR (P  0.008). We also found
haplotype-related differences for 45TG/
276GT regarding the change in adi-
ponectin levels (P  0.03). TG/TG
subjects had a mean adiponectin increase
of 0.71  0.35 g/ml (16.3%) after the
12-week trial, whereas X/X subjects
showed a mean adiponectin decrease of
0.19  0.21 g/ml (3.8%).
Effect of the ADIPOQ 45–276
haplotype on HOMA-IR indexes and
adiponectin levels in response to the
12-week dietary intervention in
relation to BMI
The subjects were divided into two sub-
groups according to individual BMI val-
ues, either 25 kg/m2 (normal-weight)
or 25 kg/m2 (overweight-obese). We
evaluated the effects of BMI on changes in
HOMA-IR indexes and plasma adiponec-
tin levels in association with the 45–276
haplotype. As expected, the two BMI sub-
groups differed significantly in baseline
values of adiponectin (5.1  0.26 vs.
4.4  0.25 g/ml, P  0.05), insulin
(8.2  0.32 vs. 11.4  0.50 U/ml, P 
0.001), and HOMA-IR (2.67  0.12 vs.
3.65  0.17, P  0.001); however, no
significant difference was found in glu-
cose levels (133  2.2 vs. 130  2.3 mg/
dl).
In the normal-weight subgroup, there
were no significant differences in either
baseline or change values for HOMA-IR
and adiponectin after dietary intervention
among the three 45–276 haplotype
groups (Fig. 1). However, in the over-
weight-obese group, TG haplotype carri-
ers had significantly higher baseline
HOMA-IR values than non-TG carriers
(TG/TG 4.2  0.45, TG/X 3.9  0.24,
and X/X 2.9  0.27, P 0.009) (Fig. 1).
After dietary intervention, HOMA-IR in-
dexes were significantly reduced in over-
weight-obese subjects with the TG/TG
haplotype, but not with either the TG/X
or the X/X haplotype. A significant differ-
ence was observed in HOMA-IR indexes
according to the 45–276 haplotypes
(TG/TG 1.05  0.31, TG/X 0.43 
0.19, and X/X 0.46  0.26, P  0.001),
even after adjustment for baseline
HOMA-IR (P  0.017). We also found
haplotype-related differences for changes
in adiponectin levels (P  0.017). After
dietary intervention, overweight-obese
subjects with the TG/TG haplotype had a
mean adiponectin increase of 1.09 0.61
g/ml (26.2%), whereas those with the
X/X haplotype had a mean adiponectin
decrease of 0.33  0.28 g/ml (7.9%).
In addition, circulating adiponectin levels
after the 12-week program in the over-
weight-obese subjects with the TG haplo-
type were higher than those in non-TG
carriers (X/X) (Fig. 1).
Finally, a multiple linear regression
analysis was performed to find the inde-
pendent effects of the ADIPOQ 45–276
haplotype as well as sex, age, BMI, base-
line values of glucose, insulin, and adi-
ponectin and change values of glucose,
insulin, and adiponectin in the total
group and subgroups according to BMI.
In the total group, the ADIPOQ 45–276
haplotype (standardized 	  0.154,
P  0.025), baseline insulin levels (stan-
dardized 	  0.188, P 0.041), base-
line adiponectin levels (standardized 	
0.159, P  0.034), and changes of in-
Table 1—Effects of a 12-week dietary intervention on anthropometric and biochemical
markers
Before After P value*
Weight (kg) 67.5  0.56 67.1  0.54 0.001
BMI (kg/m2) 25.3  0.16 25.1  0.15 0.001
Systolic blood pressure (mmHg) 130.5  0.92 126.8  0.92 0.001
Diastolic blood pressure (mmHg) 79.4  0.58 77.3  0.61 0.001
Glucose (mg/dl)† 131.2  1.64 123.2  1.83 0.001
Insulin (U/ml)† 10.0  0.37 9.50  0.30 0.259
HOMA-IR†‡ 3.24  0.13 2.88  0.10 0.001
Triglycerides (mg/dl)† 162.9  5.49 154.8  5.53 0.012
Total cholesterol (mg/dl) 198.7  1.95 191.2  2.03 0.001
LDL cholesterol (mg/dl) 122.9  1.72 115.1  1.85 0.001
HDL cholesterol (mg/dl) 45.7  0.65 47.2  0.66 0.001
Adiponectin (g/ml)† 4.75  0.18 4.98  0.21 0.351
Total energy expenditure (kcal) 2,243  19 2,281  18 0.001
Estimates of daily nutrient intake
Energy intake (kcal) 2,342  19 2,264  19 0.001
Carbohydrate (%) 62  0.43 55  0.41 0.001
Protein (%) 17  0.15 20  0.16 0.001
Fat (%) 21  0.30 24  0.39 0.001
Crude fiber (g)† 11  0.23 15  0.25 0.001
PUFA/SFA† 1.42  0.05 1.52  0.06 0.019
Data are means  SE. n  363. *Tested by paired t test. †Tested by logarithmic transformation. ‡HOMA-
IR  (fasting insulin 
microunits per milliliter  fasting glucose 
millimoles per liter)/22.5. PUFA/SFA,
polyunsaturated fatty acids–to–saturated fatty acids ratio.
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sulin levels (standardized 	  0.200,
P  0.018) showed independent effects
on adiponectin levels after dietary inter-
vention. In a subgroup analysis, changes
in adiponectin levels were affected by
only baseline adiponectin levels (stan-
dardized 	  0.372, P  0.001) in
the normal-weight group and only the
ADIPOQ polymorphism (standardized
	  0.214, P  0.033) in the over-
weight-obese group.
Relationship between changes in
plasma adiponectin level and
metabolic parameters
Overall, changes in adiponectin levels
were negatively correlated with changes
in both insulin levels (r  0.16, P 
0.022) and HOMA-IR (r  0.15, P 
0.028) after adjustment for age, sex, and
changes in body weight. After adjust-
ments for those, changes in adiponectin
levels were negatively correlated with
baseline adiponectin levels (r  0.32,
P 0.001) in normal-weight subjects and
negatively correlated with changes in in-
sulin levels (r  0.20, P  0.044) and
changes in HOMA-IR indexes (r 
0.23, P  0.020) in overweight-obese
subjects.
CONCLUSIONS— The most rele-
vant finding from our study is that the
genetic variability at the ADIPOQ locus
influences the ability of dietary interven-
tion to alter insulin resistance as mea-
sured by HOMA-IR indexes in subjects
with IFG or newly diagnosed type 2 dia-
betes. Similarly, Kang et al. (13) reported
on the role of specific ADIPOQ variants in
modulating interindividual differences in
the response to drug treatment in type 2
diabetic patients.
We examined three ADIPOQ SNPs
that had previously been suggested to af-
fect HOMA-IR: 45TG, 276GT, and
11377CG. For the 11377CG
SNP, we found no genotype-dependent
differences in HOMA-IR indexes and adi-
ponectin levels in response to dietary in-
tervention. Although previous findings
have suggested that SNPs 11391 and
11377 are associated with adiponectin
levels and contribute to the development
of type 2 diabetes, these studies were per-
formed in Caucasians (3,5). Thus, the dis-
crepancy may be explained by ethnic
differences. In fact, the 11391 SNP at
the ADIPOQ promoter region was mono-
morphic in this study population (G:A 
1:0), and it is also not found in either the
Japanese or Chinese population (4,14).
Fasting serum glucose levels were de-
creased in all three SNP 45TG geno-
types after dietary intervention. However,
subjects with the SNP 45TT genotype had
an increase in adiponectin levels and a
decrease in HOMA-IR indexes. Similarly,
in haplotype analysis for ADIPOQ
45TG/276GT, subjects with the
TG/TG haplotype had a 21% decrease in
HOMA-IR indexes and a greater increase
in adiponectin levels after dietary inter-
vention. Zacharova et al. (15) also found
that the SNP 45G allele predicts the con-
version to type 2 diabetes in subjects with
impaired glucose tolerance despite regu-
lar exercise and either a weight-reducing
or a weight-maintaining diet. Further-
more, the combined effects of the 45G
allele and the 276T allele on the conver-
sion from impaired glucose tolerance to
type 2 diabetes were observed to be stron-
ger than that of each SNP alone (15).
BMI is another factor in the response
to dietary intervention. At baseline, the
high HOMA-IR index observed among
subjects with the TG/TG haplotype was
only seen in the overweight-obese sub-
group. This result is in accordance with
Jang et al. (7) who found an association
between the TG haplotype and increased
HOMA-IR index in overweight-obese but
not in normal-weight nondiabetic Kore-
ans. In response to dietary intervention,
overweight-obese subjects carrying the
TG/TG haplotype exhibited an increase in
adiponectin levels (1.09 g/ml) and a
25% decrease in HOMA-IR index. This
finding might indicate that a genotypic-
specific effect is heightened in overweight-
obese individuals in terms of altered
adiponectin levels and HOMA-IR index
after dietary intervention compared with
normal-weight individuals. However,
these results must be interpreted with
caution. They do not mean that normal-
weight subjects have a relatively poor out-
come after dietary intervention compared
with overweight-obese subjects. More-
over, it remains unclear whether adi-
ponectin levels change according to
ADIPOQ SNPs and whether this change is
clinically relevant for long-term dietary
intervention programs.
Even though several reports have
shown an interaction between ADIPOQ
SNPs and obesity (5,8,16), the mecha-
nism is not yet known. One possible ex-
planation might be that obesity with
increased adipose tissue predispose indi-
viduals to altered adipocytokine levels
(e.g., decreased adiponectin and in-
creased tumor necrosis factor-) and,
thus, the effect of the adiponectin gene is
more exaggerated in obesity. Another
possibility is that lower baseline adi-
ponectin levels in obesity might induce
additional changes in adiponectin levels
and amplify the diet-intervention effect.
Indeed, a multiple regression analysis in
this study showed that baseline adiponec-
tin levels were independent factors to de-
termine changes in adiponectin levels.
Also, there are several reports to suggest
the relationship between adiponectin lev-
els and treatment responses (17,18).
However, further experimental studies
are needed to clarify the mechanism un-
derlying these responses.
Small differences in adiponectin lev-
els can have clinical significance (19). Our
findings that a small increase in adiponec-
tin (1.09 g/ml) along with a decrease in
both fasting insulin and glucose levels in
overweight-obese subjects carrying the
TG/TG haplotype confirm a previous re-
port of the insulin-sensitizing effects of
adiponectin (19). In the TG/TG haplo-
type group, the insulin-sensitizing effects
of adiponectin compensate for insulin
and result in a decreased demand for
insulin and improvement in the insulin
resistance index. This hypothesis might
be supported by the observation that
overweight-obese subjects carrying
non-TG alleles showed a decrease in adi-
ponectin levels (0.33 g/ml) and a slight,
although insignificant, increase in
HOMA-IR indexes. Thus, we also ob-
served an inverse relationship between
changes in HOMA-IR indexes and adi-
ponectin levels similar to previous find-
ings (18,20).
Fumeron et al. (21) found that varia-
tions at the adiponectin locus affect body
weight gain, onset of hyperglycemia, and
adiponectin levels in a 3-year prospective
study in French Caucasians. Specifically,
GG carriers of SNP 45TG were found to
gain more weight and have a higher risk of
hyperglycemia. In this study, however,
45GG subjects or subjects who did not
carry the TG haplotype of 45TG/
276GT showed no significant changes
in body weight, fasting glucose and insu-
lin levels, HOMA-IR indexes, or adi-
ponectin levels either before or after
dietary intervention. This discrepancy
might be due to either the ethnic specific-
ity or the short-term effects of dietary
changes.
There is also a conflicting report by
Nelson et al. (22) in which adiponectin
levels are altered independently ofADIPOQ
polymorphisms after dietary supplemen-
Chung and Associates
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tation with -linolenic acid. Because
small sample size (n 57) in the previous
study cannot allow interpretation of the
genetic effect, a possible assumption can
be made that specific effects of dietary fac-
tors (i.e., high -3 fatty acids) can mask
the genetic effects in relatively insulin-
sensitive healthy subjects. In addition, di-
rect comparisons between studies are
difficult, considering the differences in
the characteristics of the subjects studied
(healthy, young, primarily female, and
Caucasian versus hyperglycemic patients,
middle-aged, fewer female, and Korean)
and study intervention program.
There are several limitations in our
study design that should be mentioned.
First, dietary intake was based on self-
reports obtained from weighed food.
However, measurement errors from self-
reported dietary intake and lifestyle vari-
ables have been shown to be relatively
small (23). In this study, well-controlled,
fasting glucose concentrations reflected
the compliance of the subjects to dietary
intervention. Second, because of the small
sample size, the results of genetic analyses
should be interpreted with caution. Finally,
heterogeneity in the causes of predisposi-
tion to diabetes and diabetes itself must be
considered because metabolic differences
can be present between subjects with IFG
and type 2 diabetes. However, our patients
with newly diagnosed type 2 diabetes did
not show different metabolic characteris-
tics, including plasma adiponectin levels,
compared with those in subjects with IFG
(data not shown). Further additional stud-
ies with a larger sample size are needed to
confirm our findings.
Despite these limitations, we showed
that ADIPOQ genetic variants can be fac-
tors in the interindividual differences in
adiponectin levels and insulin resistance
indexes after dietary intervention in hy-
perglycemic patients. We found the great-
est decrease in HOMA-IR indexes and
greatest increase in adiponectin levels in
overweight-obese subjects with IFG or
newly diagnosed type 2 diabetes who
carry the TG/TG haplotype of ADIPOQ
45TG/276GT. However, long-term
prospective studies are needed to exam-
ine the relationship between adiponectin
levels and clinical outcomes in these sub-
jects. With a more complete understand-
ing of these factors, our results provide
good evidence for tailoring of dietary in-
tervention programs to individuals on the
basis of their genetic patterns.T
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Figure 1—HOMA-IR indexes and circulating adiponectin levels before (▫) and after () dietary treatment and mean changes sorted by ADIPOQ
45TG/276GT haplotype according to BMI (A: normal-weight; B: overweight-obese). P1, unadjusted P value; P2, baseline-adjusted P value. †P
 0.05 and ††P  0.01 compared with baseline values in each haplotype group tested by paired t test. P  0.05 compared with the TG/TG
haplotype and *P  0.05 compared with the TG/X haplotype tested by ANOVA with the Bonferroni method.
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